HELP

SEC filing HELP Adds Langer, Brannan to SAB; Advances NSAs for Depression, Anxiety

39d ago

SEC filing HELP CEO Transition: Michael Cola Steps Down, Eric So Resumes Interim CEO Role; APPROACH Trial Readout Q4

42d ago

News Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research

43d ago

News Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains

43d ago

SEC filing HELP Appoints Dr. Ken Kramer SVP Medical Affairs with 25Yr Neuroscience Experience, Former BMS Lead, Breakthrough Therapy Designation

47d ago

SEC filing HELP Appoints Jill Conwell Chief People Officer, 20+ Years Pharma HR Experience, Supports Pipeline Growth

81d ago

SEC filing HELP Reports $0 Revenue, $0 EPS, Phase 2 GAD Study Shows 10-Point HAM-A Improvement, 67% Responders, 39% Remission, 90-Minute Acute Effects, No Serious AEs

89d ago

SEC filing HELP Reports No Material Events, No Updates to Financials or Operations

89d ago

SEC filing HELP Publishes Nature Medicine Phase 2a SPL026 MDD Trial Results Showing -7.35 MADRS Reduction, 35% Response, 29% Remission, Phase 2 GAD Data Expected Q1 2026

104d ago

News Cybin GAAP EPS of -$1.00 misses by $0.41

109d ago

SEC filing HELP Reports $290M Assets, $101M Net Loss, ($3.40) EPS

109d ago